Adicet Bio, Inc. (ACET) is a leading biotechnology company located in Menlo Park, California. It is dedicated to creating the next generation of cell therapies primarily focused on cancer treatment. Their central principle is to provide patients with superior forms of therapeutic cells, manipulated to improve their capability to target and eliminate cancer cells.
Adicet Bio, Inc., which is publicly traded on the NASDAQ under the symbol ACET, differentiates itself through its innovative science and technology. The company's operations revolve around developing "off-the-shelf" allogeneic gamma delta T cells that can be universally applicable for all patients. These improved cells are not only capable of targeting and killing cancer cells, but they can also survive within the human body, thereby providing long-term immune assistance.
Established in 2015, the company was birthed from a core understanding of the breakthrough potential of immune cell therapies for treating cancer. Since then, Adicet Bio, Inc. has built a solid reputation for innovation, reliability, and patient focus. Each day, its team of seasoned scientists, clinicians, and drug developers work tirelessly to progress the industry and transform patient care.
Adicet Bio, Inc.'s pipeline includes several investigational cell therapies for various types of cancer. Their lead product, ADI-001, an allogeneic CAR Gamma Delta T cell therapy, is currently in Phase 1 clinical trials for treating Non-Hodgkin's lymphoma. This pioneering method stands as the symbol of Adicet Bio, Inc.'s unwavering commitment to making future cancer treatments safer, more effective, and globally accessible.
The company’s partnerships with other corporations, universities, and research institutions play a vital role in its program. One notable partnership is with Regeneron Pharmaceuticals, Inc. This partnership aims to develop new immune cell therapies using Adicet's gamma delta T cell platform in combination with Regeneron's VelociSuite® technologies.
Adicet Bio, Inc. is not merely a biotechnology company but a transformer of cancer therapy. It drives scientific innovation to gear toward a future where immune cell therapy will become a mainstream form of treatment. Hence, it continues to strive to extend and improve the lives of patients worldwide, defining a new era in immunology and oncology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Adicet Bio Inc. has reported an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This news was delivered by Quantisnow, a real-time market data and news platform that aggregates various financial information for investors. The report highlights Adicet Bio's activities, including SEC filings and participation in investor conferences.
Adicet Bio, Inc. (ACET) has presented positive data for its drug candidate, Prula-cel, and is making plans for a pivotal study in lupus nephritis. This information was shared in a slide deck published by the company. The article was written by the SA Transcripts team, which regularly publishes earnings call transcripts.
Adicet Bio's (Nasdaq: ACET) allogeneic gamma delta CAR-T therapy, prula-cel, demonstrated a 50% complete renal response rate and 54% DORIS remission in evaluable lupus nephritis (LN) patients at 12 months in a Phase I study. The company plans to initiate a pivotal LN study in Q4 2026, having aligned with the US FDA on a single-arm study design. This investigational therapy aims to deplete B cells and showed a favorable safety profile.
Adicet Bio reported positive Phase 1 data for its investigational CAR-T therapy, prula-cel, in lupus patients, showing 54% DORIS remission and 50% complete renal response in lupus nephritis patients at 12 months. These results support the company's plans to initiate pivotal study start-up activities in Q4 2026 for lupus nephritis, with potential for inclusion of non-nephritis SLE patients. The therapy demonstrated a manageable safety profile with no severe CRS, and all patients discontinued immunosuppressants.